Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of ODM-108 in Healthy Volunteers
NCT02432664Phase 1Terminated
- Sponsor
- Orion Corporation
- Start
- Apr 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ODM-108 in neuropathic pain (6 arms), sponsored by Orion Corporation. Primary endpoint: Number of participants with adverse events at 8 weeks. Started Apr 2015; status: terminated.
02
Drugs
ODM-108
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT02432664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432664.